Filtered By:
Specialty: Cardiology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 3637 results found since Jan 2013.
Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial
CONCLUSIONS: After percutaneous coronary intervention for acute coronary syndrome, women demonstrated worse clinical outcomes than men. Ticagrelor monotherapy after 3-month dual-antiplatelet therapy was associated with significantly lower risk of net adverse clinical events in women without sex interaction.PMID:37021576 | DOI:10.1161/ATVBAHA.122.318725
Source: Arteriosclerosis, Thrombosis and Vascular Biology - April 6, 2023 Category: Cardiology Authors: Bom Lee Seung-Jun Lee Byeong-Keuk Kim Yong-Joon Lee Sung-Jin Hong Chul-Min Ahn Jung-Sun Kim Young-Guk Ko Donghoon Choi Meyong-Ki Hong Yangsoo Jang Source Type: research
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale
Nature Reviews Cardiology, Published online: 05 April 2023; doi:10.1038/s41569-023-00872-4Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.
Source: Nature Reviews Cardiology - April 5, 2023 Category: Cardiology Authors: Bruna Gigante Hugo ten Cate Source Type: research
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Significant Mitral Stenosis —a Preliminary Meta-Analysis
ConclusionsDOACs were similar to warfarin in the efficacy and safety profiles in patients with AF and concomitant significant MS. Future evidence is expected from other large trials.
Source: Cardiovascular Drugs and Therapy - April 4, 2023 Category: Cardiology Source Type: research
Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III
CONCLUSIONS: This integrated analysis supports the findings of PRASTRO-III. Prasugrel is a promising treatment that results in a numerical reduction in the composite incidence of ischemic stroke, MI, and death from other vascular causes in patients with ischemic stroke who are at a high risk of stroke recurrence. No major safety issues were observed for prasugrel.PMID:37011599 | DOI:10.1159/000529149
Source: Atherosclerosis - April 3, 2023 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Toshiaki Shirai Atsushi Takita Takeshi Kuroda Kazumi Kimura Source Type: research
MELD-score for risk stratification in cardiac surgery
AbstractThe outcome of the patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) is also influenced by the renal and hepatic organ functions. Risk stratification, using scores such as EURO Score II or STS Short-Term Risk Calculator for patients undergoing cardiac surgery with cardiopulmonary bypass, ignores the quantitative renal and hepatic function; therefore, MELD-Score was applied in these cases. We retrospectively examined patient data using the MELD score as a predictor of mortality. To perform a univariate analysis of the data, patients were classified into three groups based on the MELD Score: MELD ...
Source: Heart and Vessels - April 1, 2023 Category: Cardiology Source Type: research
Von Willebrand Factor Activation Assays Predict Bleeding And Other Hemocompatibility-Related Adverse Events In Patients With CF-LVAD.
Bleeding and hemocompatibility-related adverse events (HRAEs - bleeding, neurological event, stroke, arterial thrombosis, pump thrombosis, and death) remain significant in LVAD patients; changes in coagulation homeostasis, mainly due to von Willebrand Factor (vWF) structural and functional changes induced by mechanical support have been considered a major player in these adverse events. However, the specific mechanisms and the clinical correlation between coagulation profile parameters and clinical outcomes are not yet completely clarified.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Bansi Vekaria, Eleonora Avenatti, Aayush Shah, Ju Kim, Rayan Yousefzai, Imad Hussain, Ashrith Guha, Arvind Bhimaraj, Janardhana Gorthi, Jian Chen, Edward A Graviss, Duc T Nguyen, Marcos De Oliveira, Lin-Chiang Philip Chou, Erik Suarez, Thomas E. MacGilliv Tags: 193 Source Type: research
Risk Of Pump Thrombosis With Once Daily Enoxaparin For Anticoagulation Bridging In Patients With Heartmate III
Most centers bridge patients with Left Ventricular Assist Device (LVAD) with heparin drip to avoid thromboembolic complications including stroke and pump thrombosis based on data from HeartMate II. Because of improved hemocompatibility of third generation HeartMateIII (HM3), particularly the decreased risk of in-pump thrombosis, outpatient treatment dose of low molecule weight heparin (LWMH) like Enoxaparin has been used to bridge to warfarin when the INR is subtherapeutic. Once daily dosing has been used in select patients with higher bleeding risk.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Modar Alom, Gurjaspreet Bhattal, Nitin Kabra, David Rawitscher, Amit Alam, Cesar Guerrero-Miranda, Sandra Carey, Timothy George, Aasim Afzal Tags: 180 Source Type: research
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
ConclusionBased on current evidence, for stroke prevention and treatment in patients with AF, the most safe DOAC is edoxaban in terms of fatal bleeding; dabigatran in terms of major bleeding and intracranial hemorrhage and apixaban in terms of gastrointestinal bleeding. However, given the nature of indirect comparisons, more high-quality evidence from head-to-head comparisons is still needed to confirm them.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
Atrial fibrillation, cancer and anticancer drugs
Arch Cardiovasc Dis. 2023 Mar 11:S1875-2136(23)00058-X. doi: 10.1016/j.acvd.2023.02.005. Online ahead of print.ABSTRACTActive cancer is associated with an increased risk of atrial fibrillation (AF), which varies depending on the pre-existing substrate (particularly in older patients), the cancer type and stage, and the anticancer therapeutics being taken. To date, studies have not been able to identify the individual contribution of each factor. During anticancer drug therapy, AF may occur with a frequency of ≈ 15-20% according to several factors, including the patient's baseline cardiovascular toxicity risk and the AF-d...
Source: Archives of Cardiovascular Diseases - March 31, 2023 Category: Cardiology Authors: Jonaz Font Paul Milliez Alexandre-Boudjema Ouazar Frederikus A Klok Joachim Alexandre Source Type: research
Acute coronary syndrome in very elderly patients —a real-world experience
AbstractVery elderly population constitutes an increasingly larger proportion of patients admitted for acute coronary syndromes (ACS). Notably, age represents both a proxy of frailty and an exclusion criterion in clinical randomized trials, which probably contributes to lack of data and undertreatment of real-world elderly patients. The aim of the study is to describe patterns of treatment and outcome of very elderly patients with ACS. All consecutive patients aged ≥ 80 years old (yo) admitted between January 2017 and December 2019 with ACS were included. The primary endpoint was in-hospital occurrence of major adv...
Source: Heart and Vessels - March 28, 2023 Category: Cardiology Source Type: research
Long-Term Efficacy and Safety of Left Atrial Appendage Closure Procedures
Int Heart J. 2023 Mar 15. doi: 10.1536/ihj.22-639. Online ahead of print.ABSTRACTThe aim of the present single-center, nonrandomized, retrospective study was to assess the safety and long-term efficacy of percutaneous left atrial appendage closure (LAAC) procedures and to compare the different LAAC devices and therapeutic regimes in this respect.Medical data of 136 patients (pts) (mean age, 72.5 ± 7.6 years; score for atrial fibrillation stroke risk estimation [CHA2DS2-VASc], 4.6 ± 1.6; and score for estimation of major bleeding risk for patients on anticoagulant therapy [HAS-BLED], 2.6 ± 0.9) who underwent percutaneous...
Source: International Heart Journal - March 17, 2023 Category: Cardiology Authors: Anita Zadori Zsuzsanna Kis Tibor Toth Matyas Szigeti Andras Temesvari Geza Fontos No émi Nyolczas Peter Andreka Source Type: research
Left Atrial Appendage Closure During Coronary Bypass Surgery in Patients on Hemodialysis
CONCLUSIONS: Concomitant LAA closure during CABG can reduce the risk of death and stroke in ESRD-HD patients with normal sinus rhythm.PMID:36928272 | DOI:10.1253/circj.CJ-22-0573
Source: Circulation Journal - March 17, 2023 Category: Cardiology Authors: Daisuke Endo Takeshi Kinoshita Jiyoung Lee Yoichiro Machida Kosuke Nishida Yuichiro Sato Taira Yamamoto Minoru Tabata Source Type: research
